The companies will evaluate NiKang's NKT2152 in combination with AVEO's Fotivda in a phase 2 trial that is expected to begin this year. The trial will assess the combination therapy's safety and efficacy in patients who have not responded or relapsed from previous treatments.
NiKang will sponsor the study, while AVEO will co-fund it, according to a statement.
Price: 4.70, Change: -0.49, Percent Change: -9.54